Curcumin supplement study for memory fails to launch
NCT ID NCT07251985
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if a daily curcumin supplement could improve memory and attention in adults aged 50 to 85 with age-related memory complaints. Participants would have taken curcumin or a placebo for up to 12 months. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- curcumin (Theracurmin Super TS-P1)
- What this could lead to
- If it had succeeded, this could point toward a dietary supplement that helps slow age-related memory decline.
- What could go wrong
- The study was withdrawn before enrolling anyone, so no results are available. Even if conducted, earlier evidence was based on a very small sample, and supplements often fail to show clear benefits in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Started
-
Apr 2026
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Presence of age-related memory complaints; 2. Male or female aged 50 to 85 years of age at Visit 1. 3. performance on MoCA test of \>= 18 (Milani et al, 2018) 4. Ability to perform normal daily activities independently (which excludes a diagnosis of dementia). 5. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. 6. Agreement to participate in the entire study, which could last either 6 or 12 months depending on results of the interim analysis. 7. Adequate visual and auditory acuity for cognitive testing. 8. Screening laboratory tests that do not show significant medical problems that might interfere with study participation or impact cognitive test results. 9. Psychotropic medication, if used, should be stable for at least 2 weeks prior to randomization. 10. Agreement to avoid taking any curcumin, turmeric supplements or cognitive enhancing medicines or supplements during the course of the study. Exclusion Criteria 1. Allergy to curcumin 2. Presence of a condition or abnormality that in the opinion of the site Principal Investigator would compromise the safety of the patient or the quality of the data. 3. Significant cerebrovascular disease or Alzheimer disease or any other dementia. 4. Neurological or physical illnesses that can produce cognitive deterioration. 5. History of myocardial infarction within the previous year or unstable cardiac disease. 6. Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100); significant liver or pulmonary disease, or cancer; 7. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria with a change in medication or clinical symptoms with the last 3 months prior to screening (APA, 2000). 8. History of alcoholism or substance addiction in the last 15 years. 9. Current treatment for seizure disorder; 10. Abnormal laboratory values with clinical significance in the opinion of the site Principal Investigator. 11. Current unstable medical illness including delirium, worsening congestive heart failure, unstable angina, recent myocardial infarctions, acute infectious disease, severe renal or hepatic failure, severe respiratory disease, metastatic cancer, or other conditions that, in the Principal Investigator's opinion, could interfere with the analysis of safety and efficacy in this study. 12. A 2-week washout is required prior to baseline for any of the following: curcumin or turmeric supplements, any anti-inflammatory medication other than occasional use (e.g., once per week). 13. The subject may not be an immediate family member (e.g., spouse, parent, child, sibling) of personnel directly affiliated with this study, the study site or study funding agency.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cognitive function decline are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can zapping the ear during a nap boost memory?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Could a glass of Alcohol-Free wine boost your brain?
- Can a Dual-Task test predict falls in the elderly?
- Spice up your memory? a daily blend of turmeric, cinnamon, and more put to the test
- Zapping the brain to preserve memory — a precision approach puts it to the test